How effective are the second generation antipsychotics?

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue SUPPL. 2, 1998, Pages

  Buckley, Peter ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Clozapine; Olanzapine; Risperidone; Schizophrenia; Sertindole; Treatment resistance

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA;

EID: 0032427618     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Arnt J (1998) How well do memory and learning relate to pharmacological profiles? Int J Psych Clin Pract (suppl 2): S7-S14.
2. Nyberg S (1998) Relationships among extrapyramidal symptoms, antipsychotic drug doses and neuroreceptor occupancy. Int J Psych Clin Pract (suppl 2): S33-S39.
3. Kasper S (1998) A review of the benefit:risk profile of sertindole. Int J Psych Clin Pract (suppl 2): S59-S64.
4. Buckley PF (1997) New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. J Clin Pharmacol 37: 363-78.
5. Tamminga CA (1997) The promise of new drugs for schizophrenia treatment. Can J Psychiatry 42: 265-73.
6. Chustecka Z (1998) New benefits with atypicals in schizophrenia. SCRIP No 2357, 31 July: 25.
7. Schulz SC, Buckley PF (1995) Treatment-resistant schizophrenia. In: Schizophrenia (eds SR Hirsch, DR Weinberger) 469-84. Blackwell Science, Oxford.
8. Hall WB, Vestre ND, Schiele BC, Zimmerman R (1968) A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics. Dis Nervous System 29: 405-8.
9. McCreadie RG, McDonald IM (1977) High dosage haloperidol in chronic schizophrenia. Br J Psychiatry 131: 310-16.
10. Kane J, Honigfeld G, Singer J, Meltzer HY and the Clozaril Collaborative Study Group (1988) Clozapine for treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-96.
11. Schulz SC, Conley RR, Kahn EM, Alexander JE (1989) Nonresponders to neuroleptics: a distinct subtype. In: Schizophrenia: Scientific Progress (eds SC Schulz, CA Tamminga) 341-50. Oxford University Press, Oxford.
12. Brenner HD, Dencker SJ, Goldstein MJ et al (1990) Defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 551-6.
13. Sheitman BB, Lee H, Strauss R, Lieberman JA (1997) The evaluation and treatment of first-episode psychosis. Schizophr Bull 23: 653-61.
14. Wyatt RJ, Green MF (1997) Early treatment and outcome in schizophrenia: a reanalysis of the Camarillo State Hospital data. Psychol Med 27: 1263-71.
15. Buckley PF (1998) Treatment of schizophrenia: Let's talk dollars and sense. Am J Man Care 4: 369-83.
16. Conley RR, Buchanan RW (1997) Evaluation of treatment-resistant schizophrenia. Schizophr Bull 23: 663-74.
17. Honigfeld G, Arellano F, Sethi J et al (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59: 3-7.
18. Conley RR (1998) Optimizing treatment with clozapine. J Clin Psychiatry 59: 44-8.
19. Buckley PF, Ibrahim ZY, Singer B et al (1997) Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law 25: 173-81.
20. Keck PE, Wilson DR, Strakowski SM et al (1995) Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders. J Clin Psychiatry 56: 466-70.
21. Negron AE, Liederman EA, Parkadavil M et al (1996) A naturalistic outcome study of risperidone treatment among state hospital patients. Psychiatr Serv 47: 1118-20.
22. Klieser E, Lehmann E, Kinzler E et al (1995) Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 15: 455-515.
23. Bondolfi G, Dufour H, Patris M et al (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 155: 499-504.
24. Flynn SW, MacEwan GW, Altman S et al (1998) An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 31: 25-9.
25. Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457-65.
26. Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine and negative symptoms: a path analysis. Am J Psychiatry 154: 466-72.
27. Tollefson GD, Sanger TM, Lu Y, Thieme ME et al (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55: 250-7.
28. Martin J, Gomes JC, Bernardo EG et al (1997) Olanzapine in treatment-refractory schizophrenia: results of an open-labelled study. J Clin Psychiatry 58: 479-83.
29. Conley RR, Tamminga CA, Bartko JJ et al (1998) Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155: 914-20.
30. Arvantis LA, Miller BG, and the Seroquel Trial 13 Study Group (1997) Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-46.
31. Small JG, Hirsch SR, Arvantis LA et al (1997) Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 54: 549-52.
32. Perquin LMN (1998) What is the experience with sertindole in clinical practice? Int J Psych Clin Pract (suppl 2): S87-S91.
33. Kane JM (1998) Sertindole: a review of clinical efficacy. Int Clin Psychopharmacol 13 (suppl 3): S59-S64.
34. Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782-91.
35. Fogelson DL, Stembach H, Payne D (1997) A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 17: 492-4.
36. Lee AM, Knoll JL, Suppes T (1997) The atypical antipsychotic sertindole: a case series. J Clin Psychiatry 58: 410-6.
37. Geracioti T, Parker S, Lowther NB et al (1998) A case of treatment-refractory psychosis responsive to sertindole. Schizophr Res 30: 105-8.
38. Tandon R (1997) The association of EPS and negative symptoms. J Clin Psychiatry 16: 13-4.
39. Andreasen NC, Roy M-A, Flaum M (1995) Positive and negative symptoms. In: Schizophrenia (eds SR Hirsch, DR Weinberger) 28-45. Blackwell Science, Oxford.
40. Amador XF, Gorman JM (1998) Psychopathologic domains and insight in schizophrenia. In: Psychiatric Clinics of North America: Schizophrenia. (ed PF Buckley) 27-42. WB Saunders, Philadelphia.
41. Möller HJ, Muller H, Borison RL et al (1995) A PATH-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 245: 45-9.
42. Carpenter WT, Conley RR, Buchanan RW et al (1995) Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 152: 827-32.
43. Grace J, Bellus SB, Raulin ML et al (1996) Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric Serv 47: 41-5.
44. Tandon R, Silber C, Mack R. (1996) The action of sertindole on negative symptoms in schizophrenia. Presentation at the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1996.
45. Kuipers L, Leff J, Lam D (1992) Family work for schizophrenia. A practical guide. Gaskell, London.
46. Kopelowicz A, Liberman RP, Mintz J, Zarate R (1997) Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 154: 424-5.